This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Portola Pharmaceuticals (PTLA) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of 29.87% and 61.29%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Portola Pharmaceuticals (PTLA) Q3 Earnings Expected to Decline
by Zacks Equity Research
Portola Pharmaceuticals (PTLA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Portola's (PTLA) Lymphoma Candidate Gets Orphan Drug Status
by Zacks Equity Research
Portola's (PTLA) oral Syk/JAK inhibitor, cerdulatinib, secures an orphan drug designation from the FDA for treating patients with peripheral T-cell lymphoma.
Portola Pharmaceuticals (PTLA) Jumps: Stock Rises 9.1%
by Zacks Equity Research
Portola Pharmaceuticals (PTLA) shares rose more than 9% in the last trading session, amid huge volumes.
Portola Pharmaceuticals (PTLA) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Portola Pharmaceuticals (PTLA) delivered earnings and revenue surprises of -7.33% and -30.06%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Options Traders Expect Huge Moves in Portola (PTLA) Stock
by Zacks Equity Research
Portola (PTLA) needs investors to pay close attention to the stock based on moves in the options market lately.
Why Portola Pharmaceuticals (PTLA) Could Be Positioned for a Slump
by Zacks Equity Research
It seems to be a wise decision for investors to drop Portola Pharmaceuticals (PTLA) stock considering its negative estimate revision, price depreciation as well as unfavorable Zacks rank.
Company News For Dec 27, 2017
by Zacks Equity Research
Companies in the news are: MNK,SCMP,PTLA,COF and FIG
Portola's (PTLA) AndexXa BLA Review Period Extended by FDA
by Zacks Equity Research
The FDA extends the review period of Portola's (PTLA) biologics license application for AndexXa by 90 days. Its response is now deferred to May 4, 2018 instead of the earlier Feb 3 deadline.
Pfizer Presents Encouraging Eliquis Results in NVAF Patients
by Zacks Equity Research
Pfizer (PFE) and partner Bristol-Myers presented data on Eliquis which showed the potential of the drug in reducing stroke and systemic embolism in NVAF patients undergoing cardioversion.
FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa
by Zacks Equity Research
FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.
Company News for June 26, 2017
by Zacks Equity Research
Companies in the News are: BBRY,SNCR,BBBY,PTLA
Implied Volatility Surging for Portola Pharmaceuticals (PTLA) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Portola Pharmaceuticals (PTLA) stock based on the movements in the options market lately.
Portola, HealthCare Royalty Partners Ink $150 Million Deal
by Zacks Equity Research
Portola (PTLA) announced that it has signed a royalty agreement with HealthCare Royalty Partners (HCR) for $150 million.
Portola Betrixaban Accepted for Review in U.S. & EU, Stock Up
by Zacks Equity Research
Shares of Portola (PTLA) surged 33.8% after the FDA granted priority review to anticoagulant, betrixaban. Betrixaban was also accepted by the EMA for review.
A Safer Way To Short Stocks
by Brian Bolan
Shorting can be dangerous, so you have to do your homework and be sure to leverage the Zacks Rank.